Trial Profile
A phase II trial of sutent [sunitinib] in metastatic melanoma patients with KIT aberrations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2012
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- 05 Feb 2009 Planned patient numbers (40) added as reported by ClinicalTrials.gov.
- 05 Feb 2009 Actual initiation date (Sep 2007) added as reported by ClinicalTrials.gov.
- 02 Apr 2008 New trial record.